Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (Chengdu WestVac)

重组双价新型冠状病毒肺炎疫苗 (Sf9细胞) (成都威斯克)

Report date: 2025/07/07 17:53:04

Base Information

Drug NameRecombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (Chengdu WestVac)

Drug Alias NameWSK-V101C

ClassificationVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Vaccine type > Multivalent vaccine +[4]

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesChengdu WestVac Biopharma Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesChengdu WestVac Biopharma Co Ltd

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A